Search Results

Nanopharmaceutics, Inc., a clinical-stage pharmaceutical development company, announced the initiation of a Phase I clinical study with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University “A Phase 1 Adaptive Dose Escalation With Dose Expansion Study of Triapine in Combination With Temozolomide for Patients With Recurrent Glioblastoma”.

The OpenFold group, a non-profit artificial intelligence research consortium of biotech and tech firms whose goal is to develop free and open-source software tools for biology and drug discovery, is announcing the funding of new large-scale protein studies at Prof. Gabriel Rocklin’s laboratory at Northwestern University.

Caris Life Sciences® announced that Robert H. Lurie Comprehensive Cancer Center of Northwestern University has joined the Caris Precision Oncology Alliance™.

Inspira Technologies OXY B.H.N Ltd., a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, has announced the signing of a non-binding Letter of Intent with Northwestern Memorial Hospital in Chicago, Illinois.

InFlectis BioScience, a pioneer in developing first-in-class therapies for neuromuscular diseases, announces that it has been awarded a $649,601 grant from the National MS

Astellas is opening a second location of Universal Cells, its wholly owned subsidiary, at a research campus in Japan and transferring 12 roles from Universal’s Seattle location.